Identifying Kawasaki Disease With a Low Coronary Artery Aneurysm Risk

Pediatr Infect Dis J. 2023 Jul 1;42(7):608-613. doi: 10.1097/INF.0000000000003912. Epub 2023 Mar 24.

Abstract

Introduction: Kawasaki disease (KD) patients with a high risk of coronary artery aneurysm (CAA) development are well characterized and targeted for intensified primary intravenous immunoglobulin (IVIG) treatment. However, the characteristics of KD patients with a low CAA risk are less well-known.

Methods: The present study was a secondary analysis of Prospective Observational study on STRAtified treatment with Immunoglobulin plus Steroid Efficacy for Kawasaki disease (Post RAISE), a multicenter, prospective cohort study of KD patients in Japan. The target of the analysis was patients with a Kobayashi score <5 who were predicted to respond to IVIG. The incidence of CAA during the acute phase, the primary outcome, was assessed based on all echocardiographic evaluations performed between week 1 (days 5-9) and month 1 (days 20-50) after the start of primary treatment. Multivariable logistic regression was used to identify the independent risk factors of CAA during the acute phase, based on which a decision tree was created to identify a subpopulation of patients with KD with a low CAA risk.

Results: Multivariate analysis found that a baseline maximum Z score >2.5, age <12 months at fever onset, nonresponsiveness to IVIG, low neutrophils, high platelets and high C-reactive protein were independent predictors of CAA during the acute phase. The decision tree created by using these risk factors identified 679 KD patients who had a low incidence of CAA during the acute phase (4.1%) and no medium or large CAA.

Conclusions: The present study identified a KD subpopulation with a low CAA risk comprising around a quarter of the entire Post RAISE cohort.

Publication types

  • Observational Study
  • Multicenter Study

MeSH terms

  • Coronary Aneurysm* / complications
  • Coronary Aneurysm* / diagnostic imaging
  • Coronary Aneurysm* / epidemiology
  • Coronary Artery Disease* / complications
  • Coronary Vessels
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Mucocutaneous Lymph Node Syndrome* / complications
  • Mucocutaneous Lymph Node Syndrome* / drug therapy
  • Mucocutaneous Lymph Node Syndrome* / epidemiology
  • Prospective Studies
  • Retrospective Studies

Substances

  • Immunoglobulins, Intravenous